Desvenlafaxine Alternatives Compared
Desvenlafaxine | Xyrem | Provigil |
|
---|
Desvenlafaxine | Xyrem (sodium oxybate) | Provigil (modafinil) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Major Depressive Disorder, Anxiety, Weight Loss (Obesity/Overweight), ADHD, Bipolar Disorder, Depression, Fibromyalgia, Hot Flashes, Narcolepsy, Neuralgia, Panic Disorder, Post... View more |
Prescription only
Xyrem is a Schedule III controlled substance when prescribed to treat narcolepsy; however, there is a high risk of abuse associated with it and people who misuse it or sell it to other people are... View more |
Prescription only
Prescribed for Obstructive Sleep Apnea/Hypopnea Syndrome, Shift Work Sleep Disorder, Narcolepsy. Provigil may also be used for purposes not listed in this medication guide. |
||||||||||||||||||||||||
More about Desvenlafaxine | More about Xyrem (sodium oxybate) | More about Provigil (modafinil) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Desvenlafaxine has an average rating of 6.9 out of 10 from a total of 1366 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 23% reported a negative effect. |
Xyrem has an average rating of 7.7 out of 10 from a total of 107 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 14% reported a negative effect. |
Provigil has an average rating of 7.5 out of 10 from a total of 166 ratings on Drugs.com. 66% of reviewers reported a positive effect, while 16% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: desvenlafaxine side effects in more detail. |
See also: Xyrem side effects in more detail. |
See also: Provigil side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all desvenlafaxine prices |
View all Xyrem prices |
View all Provigil prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Pristiq | Other sodium oxybate brands include: Lumryz |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
11 hours |
1 hour |
15 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Moderate abuse potential
Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
Some potential for abuse
Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 470 drugs are known to interact with desvenlafaxine:
|
A total of 342 drugs are known to interact with Xyrem:
|
A total of 499 drugs are known to interact with Provigil:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
February 29, 2008 |
July 17, 2002 |
December 24, 1998 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.